基于降钙素原的方案对重症患者抗生素暴露和费用的影响
该研究为前后对照研究,纳入2017年1月1日至2020年1月31日入住某学术三级中心ICU的1793例成人患者(降钙素原前776例,降钙素原后1017例),比较引入基于降钙素原的脓毒症评估与治疗方案前后的用药、结局和总费用。结果显示,降钙素原后时期患者接受所考察广谱抗生素的几率更低(OR -0.58,CI -0.99至-0.17,p<0.01),住院死亡几率无差异(OR 0.87,CI 0.70-1.09,p=0.234)。降钙素原后每次入院总费用显著低于降钙素原前(3834.99美元 vs 4429.47美元,p<0.05),控制相关因素后每位患者总费用减少1127.18美元(-1127.18,CI -2014.74至-239.62,p=0.013)。作者认为,在重症患者中采用基于降钙素原的方案可能减少抗生素使用并显著节约费用,且不改变死亡率。
要点
- 在ICU成人脓毒症患者中,采用基于降钙素原的方案后,接受所考察广谱抗生素的几率较采用前降低(OR -0.58,CI -0.99至-0.17,p<0.01)。
- 采用基于降钙素原的方案前后,住院死亡几率无显著差异(OR 0.87,CI 0.70-1.09,p=0.234)。
- 降钙素原后时期每次入院总费用为3834.99美元,显著低于降钙素原前时期的4429.47美元(p<0.05)。
- 控制相关因素后,降钙素原后时期每位患者总费用较降钙素原前减少1127.18美元(-1127.18,CI -2014.74至-239.62,p=0.013)。
适用人群与场景
- 2017年1月1日至2020年1月31日入住某学术三级中心ICU的18岁以上成人患者,共1793例(降钙素原前776例,降钙素原后1017例)。
- 两组患者在性别、年龄(62.0岁 vs 62.6岁)、种族和合并症方面无差异。
处置流程与药物剂量
- 引入基于降钙素原的方案用于脓毒症的评估和治疗。
研究设计与关键结果
- 研究设计为前后对照研究,纳入1793例ICU成人患者,降钙素原前组776例,降钙素原后组1017例。
- 降钙素原后组患者接受所考察广谱抗生素的几率较降钙素原前组更低(OR -0.58,CI -0.99至-0.17,p<0.01)。
- 住院死亡几率在采用降钙素原方案前后无显著差异(OR 0.87,CI 0.70-1.09,p=0.234)。
- 每次入院总费用在降钙素原后组为3834.99美元,显著低于降钙素原前组的4429.47美元(p<0.05)。
- 控制相关因素后,降钙素原后组每位患者总费用减少1127.18美元(-1127.18,CI -2014.74至-239.62,p=0.013)。
证据类型、等级与局限
- 证据类型:前后对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在ICU脓毒症患者中采用基于降钙素原的方案可能减少广谱抗生素使用并显著降低费用,且不改变死亡率(作者结论)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: To examine the impact before and after adoption of a procalcitonin-based protocol to guide sepsis management has on antibiotic use, care costs, and outcomes of critically ill patients.
DESIGN: Before-after study.
SETTING: ICU of an academic tertiary care center.
PATIENTS: Adults over 18 years old admitted to the ICU from January 1, 2017, to January 31, 2020.
INTERVENTIONS: In this before-after study, we compared the use of medications, outcomes, and overall cost before and after the introduction of a procalcitonin-based protocol for evaluation and treatment of sepsis.
MEASUREMENTS AND MAIN RESULTS: The final study cohort consisted of 1,793 patients admitted to the ICU, 776 patients pre-procalcitonin and 1,017 patients in the post-procalcitonin period. Patients were not different in the pre-procalcitonin adoption period compared with post-procalcitonin adoption with regard to gender, age (62.0 vs 62.6), race, or comorbidities. Patients admitted during the post-procalcitonin adoption period were less likely to receive the examined broad-spectrum antibiotics (odds ratio, -0.58; CI, -0.99 to -0.17; p < 0.01) than patients during the pre-procalcitonin adoption period. The odds of inhospital death did not differ after procalcitonin adoption when compared with before (0.87; CI, 0.70-1.09; p = 0.234). Total charges for each admission were significantly less in the post-procalcitonin adoption period $3,834.99 compared with pre-procalcitonin adoption $4,429.47 (p < 0.05). Patients post-procalcitonin adoption incurred $1,127.18 per patient less in total charges (-1,127.18; CI, -2,014.74 to -239.62; p = 0.013) after controlling for relevant factors.
CONCLUSIONS: In critically ill patients in a large U.S. tertiary care hospital, the adoption of a procalcitonin-based protocol for evaluation and treatment of sepsis may be associated with decreased antibiotic use and significant cost savings, with no change in mortality.
参考来源
- Chow J, Markossian TW, Albarillo FS, et al. Impact of a Procalcitonin-Based Protocol on Antibiotic Exposure and Costs in Critically Ill Patients. Crit Care Explor. 2021. PMID: 34778793. doi:10.1097/CCE.0000000000000571
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。